Hyperhydration with cisplatin does not influence pemetrexed exposure

N. de Rouw*, H.J. Derijks, L.B. Hilbrands, R.J. Boosman, B. Piet, S.L.W. Koolen, J.A. Burgers, A.M.C. Dingemans, M.M. van den Heuvel, L.E.L. Hendriks, J.G.J.V. Aerts, S. Croes, R.H.J. Mathijssen, A.D.R. Huitema, D.M. Burger, B. Biesma, R. ter Heine

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)871-876
Number of pages6
JournalBritish Journal of Clinical Pharmacology
Volume88
Issue number2
Early online date26 Aug 2021
DOIs
Publication statusPublished - Feb 2022

Keywords

  • hyperhydration
  • pemetrexed
  • pharmacokinetics
  • MALIGNANT PLEURAL MESOTHELIOMA
  • PHASE-I
  • CANCER

Cite this